EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC0

Treatment of refractory poly articular course juvenile idiopathic arthritis with tofacitinib: Extended experience from Bangladesh

Kazi Iman iD, Laboni Akter, Mohammad Masudur Rahman, Kamrul Laila iD, Mohammad Imnul Islam, Shahana A Rahman iD

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0312174 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PLOS ONE, 2025. Verfasst von Kazi Iman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Dr. M R Khan Shishu Hospital & ICH, Mirpur, Dhaka, Bangladesh. Hauptthemen laut MEDLINE: Arthritis, Juvenile, Piperidines, Pyrimidines, Pyrroles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Juvenile Idiopathic arthritis (JIA) is one of the most common chronic diseases in children. It still remains a challenge to treat refractory poly-articular course JIA patients, especially in Bangladesh, where patients from low socio-economic backgrounds are unable to manage biological agents. Tofacitinib is one of the alternative options to biological agents, which can be taken orally and is cost effective. The purpose of this prospective observational study was to evaluate the efficacy of tofacitinib in the treatment of refractory poly-articular course JIA cases. Materials and methods This study was carried out in the Department of Pediatrics, Bangabandhu Sheikh Mujib Medical University (BSMMU). A total number of 50 refractory polyarticular course JIA patients received JAK-2 inhibitor, tofacitinib along with other drugs according to the recommended doses. The disease activity level was measured by Juvenile Arthritis Disease Activity Score-27 (JADAS-27). All the cases were assessed at baseline, 6 th , 12 th and52 nd week of tofacitinib therapy. The relevant statistical tests were applied for data analysis.

Results

After treating the refractory cases with tofacitinib, arthritis subsided, and laboratory parameters improved in all the cases. Overall JADAS-27 score improvement was 40.67%, 56.38% and 96% at 6 th , 12 th and 52 nd week of follow-up respectively. It was also possible to taper the dose of steroid gradually and stopped it by 24 weeks. Tofacitinib was well tolerated with minimum side effects.

Conclusions

Tofacitinib was effective to all the children with poly-articular course JIA. It was well tolerated and had very few tolerable adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, JuvenilePiperidinesPyrimidinesPyrrolesProtein Kinase InhibitorsHumansFemaleMaleChildBangladeshChild, PreschoolProspective StudiesTreatment OutcomeAdolescent

Substanzen

tofacitinibPiperidinesPyrimidinesPyrrolesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pediatrics, Dr. M R Khan Shishu Hospital & ICH, Mirpur, Dhaka, Bangladesh.
  • Department of Pediatrics, Dhaka Medical College Hospital, Dhaka, Bangladesh.
  • Pediatrics, 250 Bedded General Hospital Jamalpur, Dhaka, Bangladesh.
  • Department of Pediatrics, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka, Bangladesh.

ORCID-Profile: Kazi Iman, Kamrul Laila, Shahana A Rahman

Zitieren

APA

Iman, K., Akter, L., Rahman, M. M., Laila, K., Islam, M. I., & Rahman, S. A. (2025). Treatment of refractory poly articular course juvenile idiopathic arthritis with tofacitinib: Extended experience from Bangladesh. PLOS ONE. https://doi.org/10.1371/journal.pone.0312174

Vancouver

Iman K, Akter L, Rahman MM, Laila K, Islam MI, Rahman SA. Treatment of refractory poly articular course juvenile idiopathic arthritis with tofacitinib: Extended experience from Bangladesh. PLOS ONE. 2025. doi:10.1371/journal.pone.0312174

BibTeX
@article{Iman2025,
  author = {Iman, Kazi and Akter, Laboni and Rahman, Mohammad Masudur and Laila, Kamrul and Islam, Mohammad Imnul and Rahman, Shahana A},
  title = {Treatment of refractory poly articular course juvenile idiopathic arthritis with tofacitinib: Extended experience from Bangladesh},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0312174}
}
Kostenlos starten →